持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/05/15 | 日証協 | 148,329株 | +10.69% | 34,442株 | +43.42% | 193,275株 | -0.88% | 13,114株 | -40.39% |
2020/05/08 | 日証協 | 134,000株 | +13.75% | 24,014株 | -5.46% | 194,989株 | +11.3% | 22,000株 | -16.67% |
2020/05/01 | 日証協 | 117,800株 | -1.01% | 25,400株 | -33.85% | 175,189株 | -10.02% | 26,400株 | -22.8% |
2020/04/24 | 日証協 | 119,000株 | +19.62% | 38,396株 | +90.1% | 194,689株 | +3.41% | 34,196株 | +27.37% |
2020/04/17 | 日証協 | 99,479株 | -10.18% | 20,198株 | -71.16% | 188,268株 | -2.16% | 26,847株 | -60.96% |
2020/04/10 | 日証協 | 110,752株 | +28.83% | 70,031株 | +144.19% | 192,420株 | +5.19% | 68,761株 | -12.1% |
2020/04/03 | 日証協 | 85,967株 | -29.92% | 28,679株 | -52.75% | 182,929株 | -19.58% | 78,227株 | +12.57% |
2020/03/27 | 日証協 | 122,667株 | +26.41% | 60,700株 | +15.07% | 227,470株 | -2.35% | 69,492株 | +31.12% |
2020/03/19 | 日証協 | 97,039株 | -16.07% | 52,749株 | -26.51% | 232,934株 | +0.65% | 53,000株 | +24.98% |
2020/03/13 | 日証協 | 115,622株 | -5.22% | 71,781株 | -20.59% | 231,441株 | -9.69% | 42,408株 | -26.98% |
2020/03/06 | 日証協 | 121,984株 | -2.13% | 90,390株 | +2.97% | 256,283株 | +22.02% | 58,079株 | +10.12% |
2020/02/28 | 日証協 | 124,638株 | -10.52% | 87,787株 | -9.04% | 210,041株 | +6.09% | 52,742株 | +61.79% |
2020/02/21 | 日証協 | 139,298株 | +13.71% | 96,512株 | +14.59% | 197,980株 | +12.18% | 32,600株 | -24.19% |
2020/02/14 | 日証協 | 122,505株 | +17.86% | 84,224株 | +70.29% | 176,480株 | +5.07% | 43,004株 | -39.92% |
2020/02/07 | 日証協 | 103,937株 | -10.74% | 49,458株 | +197.22% | 167,970株 | +5.23% | 71,583株 | +181.98% |
2020/01/31 | 日証協 | 116,437株 | -11.14% | 16,640株 | -77.93% | 159,624株 | +2.02% | 25,386株 | -58.9% |
2020/01/24 | 日証協 | 131,030株 | +14.01% | 75,408株 | +80.82% | 156,467株 | -4.8% | 61,770株 | +17.97% |
2020/01/17 | 日証協 | 114,930株 | +7.18% | 41,703株 | +0.56% | 164,351株 | +1.88% | 52,362株 | -9.1% |
2020/01/10 | 日証協 | 107,230株 | -10.22% | 41,472株 | +702.17% | 161,321株 | +6.91% | 57,602株 | +638.49% |
※株式分割は考慮していませんのでご注意ください。
Page Top